Antibody Services Market Size, Share, Growth, And Industry Analysis, By Type (Monoclonal, Polyclonal & Others) by Application (BioScience Companies, BioScience Research Institutions, Hospitals & Other), Regional Insights, and Forecast To 2032

• 

   Request a Free Sample To Get More Information on this Market

ANTIBODY SERVICES MARKET REPORT OVERVIEW

The global antibody services market size was USD 2.63 billion in 2024 and market is expected to reach USD 5.4 billion by 2032, exhibiting a CAGR of 9.4% during the forecast period. North America is dominating the antibody services market share in 2024.

In the healthcare industry, antibodies are used to cure and prevent bacterial and infectious diseases. While bacteriostatic treatments stop bacteria from multiplying and spreading, bactericidal drugs destroy germs. Several diseases, including cancer, rheumatoid arthritis, and other chronic ailments are treated with monoclonal antibodies (mAbs). Because of its selectivity for cancer cells, targeted therapy is expanding quickly while avoiding harm to non-target cells. As the prevalence of cancer grows, targeted drugs are growing in popularity. A form of cancer immunotherapy known as targeted antibodies works by impairing cancer cell activity and triggering the immune system to seek out and destroy cancer cells.

Over the course of the forecast period, the antibody services market share is anticipated to rise as a result of rising demand for therapeutic antibodies, particularly monoclonal and polyclonal antibodies. The most popular biopharmaceuticals for targeting aberrant cells with precision are antibodies. As a result, a number of pharmaceutical firms have started focusing on the creation of new treatments for both acute and chronic illnesses, including cancer and rheumatoid arthritis. The impending patent expiration of multiple powerful monoclonal antibodies is another significant factor boosting the demand for antibodies. Several antibodies, including Humira, Keytruda, and Herceptin, will lose their patent protection in a few years. Many businesses are working on trastuzumab biosimilars, including Pfizer Inc. and Amgen Inc., which is anticipated to fuel antibody services market growth.

COVID-19 IMPACT

"Market Growth Favored on Account of Rising Demand for Antibodies During Lockdown"

Due to the COVID-19 pandemic's increased need for antibodies, the antibody industry has been expanding. In response to the high transmission and severe death rates, the FDA approved an Emergency Use Authorization (EUA) for three monoclonal antibodies intended for the outpatient treatment of symptomatic COVID-19 patients. In November 2020 and April 2021, respectively, the Centers for Medicare and Medicaid Services authorised monoclonal antibody treatments like "REGN-COV2" (a combination therapy comprised of 2 human monoclonal antibodies, Casirivimab & imdevimab). This aids in preventing the virus' invasion into human cells. COVID- A monoclonal antibody can be given intravenously (IV) to 19 individuals at an emergency room or an infusion centre. The National Center for Biotechnology Information reported that the federal government of the United States bought 2.5 million antibody treatments and gave 1 million to the states.

LATEST TRENDS

"Increasing Research and Development Spending to Stimulate Market Expansion"

The world's healthcare infrastructure is in development, particularly in low- and middle-income nations. The infrastructure for healthcare as well as investments in research and development of new products and treatments are what are driving antibody services market growth. The WHO estimates that in 2018, grants worth around USD 33 billion were distributed globally. The bulk (65%) of this sum was used towards research. In a similar vein, funding for the National Institutes of Health (NIH) grew by (7.3%) in 2022 compared to 2021. Because monoclonal antibodies are a viable therapy option for a number of critical disorders, such worldwide financing initiatives for healthcare research are predicted to fuel the antibody services market share for bespoke antibodies.

ANTIBODY SERVICES MARKET SEGMENTATION

By Type

Depending on antibody services given are types: monoclonal, polyclonal & others. The monoclonal type will capture the maximum market share through forecast period.

By Application

The market is divided in BioScience Companies, BioScience Research Institutions, Hospitals & Other based on application. The global antibody services market players in cover segment like bioscience companies will dominate the market share during forecast period.

DRIVING FACTORS

"The Market for Antibody Manufacturing is Expanding Due toRising Demand for Therapeutic Antibodies"

Since they have been the main form of therapy for many ailments over the past 25 years, therapeutic antibodies are becoming more and more significant. Significant technical advancements at this time have sped up and enhanced the treatment of mAbs. The U.S. Food and Drug Administration (FDA) reports that 48 unique mAbs have been approved since 2008, bringing the total number of monoclonal antibodies in clinical usage on the global market to 100 by the end of 2021. Due to the extremely active development of antibody therapies in recent decades, monoclonal antibodies have emerged as a key class of therapeutic agents in the treatment of many illnesses, including cancers, neurological, and metabolic disorders. Due to the prevalence of infectious illnesses, there is a growing demand for monoclonal antibodies worldwide. During the projected period, healthcare reforms in developing nations and increased investment in the market for antibodies manufacturing are anticipated to propel global antibody services market growth.

"Growing Healthcare Industry Research Increases Demand for Antibody Production"

The frequency of chronic diseases has significantly grown over the world, and the regular outbreaks of viral illnesses have raised attention on healthcare. Government investment on research and the creation of new medicines has grown as a result of the increasing focus on healthcare, which is anticipated to favour the antibody services market growth and potential for antibodies throughout the course of the projected period. It is anticipated that during the next years, demand for antibodies would rise due to the high frequency of uncommon illnesses and the growing usage of monoclonal and polyclonal antibodies in their treatment and diagnosis. Through 2032, it is projected that the demand for research into bespoke antibodies will increase due to the rising popularity of customised medicine.

RESTRAINING FACTORS

"A Significant Hindrance to Revenue Growth is a Shortage of Competent Workers."

The fastest-growing class of novel therapeutic chemicals that are not yet on the market are therapeutic monoclonal antibodies (mAbs). The cost is raised by the fact that the number of therapeutic antibodies that can be produced is constrained by present production and purification techniques. Therapeutic monoclonal antibody distribution by in-vivo genetic means could offer a fresh approach to addressing these issues. First of all, by maintaining therapeutic, non-toxic medication levels in the blood for a very long period, therapeutic efficacy can be improved. There may be no need for repeated high-dose bolus injections, which would lower the possibility of adverse effects. There is a probability that therapeutic antibody production and purification costs may decrease and may hinder the antibody services market size, allowing mAb gene transfer both within and outside the body an economically sensible option.

• 

   Request a Free Sample To Get Analysis on Major Geographic Market

ANTIBODY SERVICES MARKET REGIONAL INSIGHTS

"North American biopharmaceutical firms are expected to drive global demand for antibodies."

Due to a number of factors, such as an increase in the geriatric population, higher healthcare spending, ongoing growth in R&D activities, and an increase in the use of these therapeutic applications in the treatment of various disorders like PCOS (polycystic ovarian syndrome) and breast cancer in the region, the antibody services market share in North America is anticipated to account for the largest revenue share in the global market during the forecast period. For instance, a 2019 Centers for Disease Control and Prevention (CDC) research found that PCOS affects 6% to 12% of women, or more than 5 million women of reproductive age. It is one of the most common reasons of female infertility in the U.S., which is what is causing the market to rise. Furthermore, the presence of sophisticated health infrastructure and well-established direct compensation regulations are anticipated to considerably boost market

A stable revenue CAGR is anticipated for the Asia Pacific antibody services market share over the course of the forecast period as a result of rising government support, evolving disease profiles, expanding public-private partnerships, and expanded financing activities. These elements are enhancing the performance of the biotechnology sectors in Asia and the Pacific. Additionally, sizable expenditures help the region's healthcare sector embrace cutting-edge technologies. China spent the most on R&D globally in 2019, according to the Organization for Economic Co-operation and Development (OECD). Governments in the Asia-Pacific region also offer tax exemptions, cheaper lands, incubators, and direct financial help to promote the expansion of local biotechnology enterprises and enable them to improve their skills. Among the most desirable destinations for the global biotechnology sector are Malaysia, Taiwan, Singapore, India, China, and Japan.

KEY INDUSTRY PLAYERS

"Key Players Focus on Partnerships to Gain a Competitive Advantage "

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

List of Top Antibody Services Companies

• ThermoFisher (U.S)
• GenScript (U.S)
• Abcam(U.K)
• MBS (U.S)
• ROCKLAND (U.S)
• ProSci (U.S)
• Anaspec (U.S)
• Bio-Rad (U.S)
• Covance (U.S)
• Capra Science (Sweden)
• Innovagen (Sweden)
• APS (U.S)
• Randox (U.K)
• GL Biochem (China)
• Abgent (U.S)

REPORT COVERAGE

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, and restraints. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.